Item 8.01 Other Events.

On January 24, 2022, the Company issued a press release announcing the topline results from an expansion cohort of the Phase 1b/2a trial of pegozafermin for the treatment of nonalcoholic steatohepatitis. A copy of the press release is furnished herewith as Exhibit 99.1 and incorporated herein by reference.

Also on January 24, 2022, the Company made available an updated corporate presentation on the Company's website. A copy of the corporate presentation is filed herewith as Exhibit 99.2 and incorporated herein by reference.

In accordance with General Instruction B.2 of Form 8-K, the information furnished pursuant to this Item 8.01, including Exhibit 99.1, shall not be deemed to be "filed" for purposes of Section 18 of the Exchange Act or otherwise subject to the liabilities of that section, and shall not be incorporated by reference into any registration statement or other document filed under the Securities Act or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.

© Edgar Online, source Glimpses